Clear Street raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $533 from $431 and keeps a Buy rating on the shares to reflect Rezdiffra’s continued strong performance, even as Wegovy enters the F2-F3 MASH market. As a result of Rezdiffra’s sustained growth, the firm has increased its peak penetration assumption to 20% from 15% for F2-F3 MASH, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals reports Q3 EPS ($5.08) vs ($4.92) last year
- Madrigal Pharmaceuticals management to meet with Citizens
- Madrigal Pharmaceuticals upgraded to Neutral at BofA after Rezdiffra outperforms
- Madrigal Pharmaceuticals upgraded to Neutral from Underperform at BofA
- MDGL Upcoming Earnings Report: What to Expect?